信立泰：关于SAL0145药品临床试验申请获得受理的公告

Group 1 - The core point of the article is that the company Xinlitai has announced that its self-developed siRNA innovative drug SAL0145 injection has received acceptance for clinical trial application by the National Medical Products Administration, which is intended for the treatment of MASH. If approved, it will enrich the innovative product pipeline in the chronic disease sector [2] Group 2 - The drug SAL0145 is positioned to address a significant medical need in the chronic disease treatment area, indicating potential market opportunities for the company [2] - The acceptance of the clinical trial application marks a critical step in the drug development process, highlighting the company's commitment to innovation in the pharmaceutical industry [2] - The announcement reflects the ongoing trend of increasing investment in research and development for innovative therapies within the healthcare sector [2]